Poly Medicure Limited

As of June 30, 2026, Poly Medicure Limited carries a market capitalization of 171.05B, placing it among publicly traded companies globally. Its enterprise value stands at 171.05B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Poly Medicure Limited's next confirmed earnings release is scheduled for November 2, 2026.

As of June 30, 2026, Poly Medicure Limited has 101.36M shares outstanding.

As of June 30, 2026, Poly Medicure Limited trades at a trailing price-to-earnings ratio of 54.24.

As of June 30, 2026, Poly Medicure Limited trades at an EV/EBITDA multiple of 57.44 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 8.56 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 100.85 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 171.05B versus a market cap of 171.05B, with the gap driven by net debt and cash on the balance sheet.

These figures are as of June 30, 2026.

These figures cover the twelve months ended June 30, 2026. The company generates approximately 7.01M in revenue per employee across its workforce of 2,848.00, a quick read on workforce productivity versus industry peers.

Over the twelve months ended June 30, 2026, Poly Medicure Limited recorded 1.09B in income tax expense. That works out to an effective tax rate of 25.82, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 4.22B, leaving 3.14B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

As of the close on October 22, 2026, Poly Medicure Limited's stock has declined approximately 25.22% over the past 52 weeks. The 50-day moving average sits at 1,693.72, while the 200-day moving average is 1,558.53.

Over the twelve months ended June 30, 2026, Poly Medicure Limited generated 19.97B in revenue and converted that into 3.14B in net income, yielding earnings per share of 30.99. EBITDA reached 2.98B, while operating income came in at 1.76B.

Over the twelve months ended June 30, 2026, Poly Medicure Limited posted a gross margin of 61.65, reflecting its pricing power and cost economics. The operating margin of 8.83 and net profit margin of 15.71 provide insight into operational efficiency.

Poly Medicure Limited's most recent stock split took place on March 24, 2017 with a 1:2 split ratio.